How it works:
Mitomycin is a cytostatic agent that inhibits DNA synthesis in rapidly dividing cancer cells, leading to cell death and tumour reduction. It is used both systemically and locally, such as in intravesical administration for bladder cancer.
Who should use it:
Patients with gastric, pancreatic, or cervical cancer
Individuals undergoing bladder cancer treatment
Those receiving combination chemotherapy
Under oncologist supervision with regular monitoring of blood, liver and renal function
Advanced or metastatic gastric cancer
Pancreatic cancer
Cervical cancer
Superficial bladder cancer
Other malignancies as prescribed
MITOMYCIN 40 mg is administered intravenously or locally (e.g. intravesically) by a healthcare professional. Dosage and frequency are tailored to the patient’s condition, treatment goals, and tolerance. Blood tests and organ function monitoring are essential during treatment.
Known hypersensitivity to mitomycin
Severe myelosuppression
Pregnancy and lactation
Significant renal or hepatic dysfunction
Active infections
Bone marrow suppression (leukopenia, thrombocytopenia, anaemia)
Gastrointestinal disturbances (nausea, vomiting)
Increased risk of infections
Renal toxicity
Pulmonary toxicity (pneumonitis, fibrosis)
Injection site inflammation or pain
